↓ Skip to main content

Cannabinoid‐1 receptor antagonist rimonabant (SR141716) increases striatal dopamine D2 receptor availability

Overview of attention for article published in Addiction Biology, September 2011
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
31 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cannabinoid‐1 receptor antagonist rimonabant (SR141716) increases striatal dopamine D2 receptor availability
Published in
Addiction Biology, September 2011
DOI 10.1111/j.1369-1600.2011.00369.x
Pubmed ID
Authors

Cleo L. Crunelle, Elsmarieke van de Giessen, Sybille Schulz, Louk J. M. J. Vanderschuren, Kora de Bruin, Wim van den Brink, Jan Booij

Abstract

The cannabinoid 1 receptor antagonist rimonabant (SR141716) alters rewarding properties and intake of food and drugs. Additionally, striatal dopamine D2 receptor (DRD2) availability has been implicated in reward function. This study shows that chronic treatment of rats with rimonabant (1.0 and 3.0 mg/kg/day) dose-dependently increased DRD2 availability in the dorsal striatum (14 and 23%) compared with vehicle. High-dose rimonabant also increased DRD2 availability in the ventral striatum (12%) and reduced weight gain. Thus, up-regulation of striatal DRD2 by chronic rimonabant administration may be an underlying mechanism of action and confirms the interactions of the endocannabinoid and dopaminergic systems.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 31 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 9 29%
Researcher 6 19%
Other 3 10%
Student > Master 3 10%
Student > Bachelor 2 6%
Other 5 16%
Unknown 3 10%
Readers by discipline Count As %
Medicine and Dentistry 6 19%
Neuroscience 6 19%
Agricultural and Biological Sciences 5 16%
Psychology 4 13%
Biochemistry, Genetics and Molecular Biology 2 6%
Other 1 3%
Unknown 7 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 September 2014.
All research outputs
#20,655,488
of 25,371,288 outputs
Outputs from Addiction Biology
#979
of 1,171 outputs
Outputs of similar age
#119,920
of 143,310 outputs
Outputs of similar age from Addiction Biology
#13
of 21 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,171 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one is in the 8th percentile – i.e., 8% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 143,310 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.